Yezan Munther Haddadin bought $24K of OTLK stock

Yezan Munther Haddadin, Dir of Outlook Therapeutics, Inc. (OTLK), bought 29,000 shares of OTLK stock worth $24K, per an SEC Form 4 filed Jun 3, 2026.

It was an open-market purchase.

The trade happened on Jun 2, 2026, 1 day before it was made public.

OTLK has moved -49.2% since the trade date, from $0.81 to $0.41 (Nov 13, 2026 close).